Differences in both matrix metalloproteinase 9 concentration and zymographic profile between plasma and serum with clot activators are due to the presence of amorphous silica or silicate salts in blood collection devices

Analytical Biochemistry

Volumn 374, Issue 1, 2008, Pages 56-63

  Mannello, Ferdinando ^a   Tanus Santos, Jose E ^b   Meschiari, Cesar A ^b   Tonti, Gaetana A ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Buffy coat; Clot activator; Matrix metalloproteinases; Peripheral blood; Plasma; Serum; Silica; Silicate; U 937 leukemia cells

Indexed keywords

ADDITIVES; BLOOD; DISEASES; GLASS; PLASMAS; SILICATES;

BUFFY COAT; CLOT ACTIVATOR; LEUKEMIA CELLS; MATRIX METALLOPROTEINASES; PERIPHERAL BLOOD; SERUM;

SILICA;

GELATINASE A; GELATINASE B; GLASS; PLASTIC; SILICATE; SILICON DIOXIDE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; ZYMOGRAPHY;

EID: 38349129173     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2007.11.020     Document Type: Article

References (45)

1. McCawley L.J., and Matrisian L.M. Matrix metalloproteinases: They're not just for matrix anymore!. Curr. Opin. Cell Biol. 13 (2001) 534-540
2. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: An overview. Front. Biosci. 11 (2006) 1696-1701
3. Mannello F., Luchetti F., Falcieri E., and Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 10 (2005) 19-24
4. Mannello F., and Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: Conundrums, controversies, and potential implications. Apoptosis 6 (2001) 479-482
5. Mannello F., Tonti G.A., and Papa S. Matrix metalloproteinase inhibitors as anti-cancer therapeutics. Curr. Cancer Drug Targets 5 (2005) 285-298
6. Zucker S., Hymowitz M., Conner C., Zarrabi H.M., Hurewitz A.N., Matrisian L., Boyd D., Nicolson G., and Montana S. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Ann. N.Y. Acad. Sci. 878 (1999) 212-227
7. Zucker S., Lysik R.M., Gurfinkel M., Zarrabi M.H., Stetler-Stevenson W., Liotta L.A., Birkedal-Hansen H., and Mann W. Immunoassay of type IV collagenase/gelatinase (MMP-2) in human plasma. J. Immunol. Methods 148 (1992) 189-198
8. Jung K., Nowak L., Lein M., Henke W., Schnorr D., and Loening S.A. Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. Clin. Chem. 42 (1996) 2043-2045
9. Lein M., Nowak L., Jung K., Koenig F., Lichtinghagen R., Schnorr D., and Loening S.A. Analytical aspects regarding the measurements of metalloproteinases and their inhibitors in blood. Clin. Biochem. 30 (1997) 491-496
10. Jung K., Laube C., Lein M., Lichtinghagen R., Tschesche H., Schnorr D., and Loening S.A. Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. Clin. Chem. 44 (1998) 1060-1062
11. Jung K., Lein M., Laube C., and Lichtinghagen R. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin. Chim. Acta 314 (2001) 241-244
12. Jung K., and Lichtinghagen R. Circulating gelatinase B (MMP-9): The impact of preanalytical step of blood collection. Matrix Biol. 21 (2002) 381-382
13. Makowski G.S., and Ramsby M.L. Use of citrate to minimize neutrophil matrix metalloproteinase-9 in human plasma. Anal. Biochem. 322 (2003) 283-286
14. Mannello F. Effects of blood collection methods on gelatin zymography of matrix metalloproteinases. Clin. Chem. 49 (2003) 339-340
15. Mannello F., Luchetti F., Canonico B., and Papa S. Effects of anticoagulants and cell separation media as preanalytical determinants on zymographic analysis of plasma matrix metalloproteinases. Clin. Chem. 49 (2003) 1956-1957
16. Jung K., Meisser A., and Bischof P. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes. Intl. J. Cancer 116 (2005) 1000-1001
17. Meisser A., Cohen M., and Bischof P. Concentrations of circulating gelatinases (matrix metalloproteinase-2 and -9) are dependent on the conditions of blood collection. Clin. Chem. 51 (2005) 274-276
18. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., and Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal. Biochem. 344 (2005) 147-149
19. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin. Biochem. 38 (2005) 410-414
20. Thrailkill K., Cockrell G., Simpson P., Moreau C., Fowlkes J., and Bunn R.C. Physiological matrix metalloproteinase (MMP) concentrations: Comparison of serum and plasma specimens. Clin. Chem. Lab. Med. 44 (2006) 503-504
21. Jung K. Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases. Clin. Chem. Lab. Med. 44 (2006) 501-502
22. Jung K., Gerlach R.F., and Tanus-Santos J.E. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. Clin. Chim. Acta 373 (2006) 180-181
23. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem. 40 (2007) 119-123
24. Fernandez-Patron C., Martinez-Cuesta M.A., Salas E., Sawicki G., Wozniak M., Radomski M.W., and Davidge S.T. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb. Haemost. 82 (1999) 1730-1735
25. Opdenakker G., Van den Steen P.E., Dubois B., Nelissen I., Van Coillie E., Masure S., Proost P., and Van Damme J. Gelatinase B functions as regulator and effector in leukocyte biology. J. Leuk. Biol. 69 (2001) 851-859
26. Mannello F F., and Tonti G.A. Gelatinase concentrations and zymographic profiles in human breast cancer: Matrix metalloproteinases circulating in plasma are better markers for the sub-classification and early prediction of cancer: The coagulation/fibrinolysis pathways alter the release, activation, and recovery of different gelatinases in serum. Intl. J. Cancer 121 (2007) 216-218
27. Drake S.K., Bowen R.A.R., Remaley A.T., and Hortin G.L. Potential interference from blood collection tubes in mass spectrometric analyses of serum polypeptides. Clin. Chem. 50 (2004) 2398-2401
28. Banks R.E., Stanley A.J., Cairns D.A., Barrett J.H., Clarke P., Thompson D., and Selby P.J. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 51 (2005) 1637-1649
29. Pilny R., Bouchal P., Borilova S., Ceskova P., Zaloudik J., Vyzula R., Vojtesek B., and Valik D. Surface-enhanced laser desorption ionization/time-of-flight mass spectrometry reveals significant artefacts in serum obtained from clot activator-containing collection devices. Clin. Chem. 52 (2006) 2115-2116
30. Timms J.F., Arslan-Low E., Gentry-Maharaj A., Luo Z., T'Jampens D., Podust V.N., Ford J., Fung E.T., Gammerman A., Jacobs I., and Menon U. Preanalytical influence of sample handling on SELDI-TOF serum protein profile,. Clin. Chem. 53 (2007) 645-656
31. Mannello F., Tonti G.A., Tanus-Santos J.E., and Gerlach R.F. Silica increases the release of MMP-9 forms in peripheral blood: Why gelatin zymography differs significantly between citrate plasma and serum obtained with/without clot activators. Clin. Chem. 53 (2007) 1981-1982
32. Becton Dickinson Vacutainer brand SST tubes containing silica and gel, material safety data sheet, http://catalog.bd.com/ecat/msds/d01/vs60313.pdf.
33. Sarstedt S-Monovette tubes containing silica and gel, material safety data sheet, http://www.sarstedt.com.
34. Mannello F., and Sebastiani M. Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids. Clin. Chem. 49 (2003) 1546-1550
35. Bodo M., Bellocchio S., Bellucci C., Balloni S., Pietrella D., Sbaraglia G., Muzi G., Lilli C., Lumare A., Dell'Omo M., and Abbritti G. Silica, hyaluronate, and alveolar macrophage functional differentiation. J. Invest. Med. 51 (2003) 95-103
36. Hu S., Zhao H., Al-Humadi N.H., Yin X.J., and Ma J.K. Silica-induced apoptosis in alveolar macrophage: Evidence of in vivo thiol depletion and the activation of mitochondrial pathway. J. Toxicol. Environ. Health A 69 (2006) 1261-1284
37. Brown J.M., Swindle E.J., Kushnir-Sukhov N.M., Holian A., and Metcalfe D.D. Silica-directed mast cell activation is enhanced by scavenger receptors. Am. J. Respir. Cell Mol. Biol. 36 (2007) 43-52
38. Ramstrom S. Clotting time analysis of citrated blood samples is strongly affected by the tube used for blood sampling. Blood Coagul. Fibrinolysis 16 (2005) 447-452
39. Fiebig E.W., Etzell J.E., and Ng W.L. Clinically relevant differences in prothrombin time and INR values related to blood sample collection in plastic vs. glass tubes. Am. J. Clin. Pathol. 124 (2005) 902-909
40. Kratz A., Stanganelli N.B., and Van Cott E.M. A comparison of glass and plastic blood collection tubes for routine and specialized coagulation assays: A comprehensive study. Arch. Pathol. Lab. Med. 130 (2006) 39-44
41. Toulon P., Ajzemberg N., Smahi M., and Guillin M.C. A new plastic collection tube made of polyethylene terephthalate is suitable for monitoring traditional anticoagulant therapy (oral anticoagulant, unfractioned heparin, low molecular weight heparin). Thromb. Res. 119 (2007) 135-143
42. Perez-Ramos J., de Lourdes Segura-Valdez M., Vanda B., Selman M., and Pardo A. Matrix metalloproteinases 2, 9, and 13, and tissue inhibitors of metalloproteinases 1 and 2 in experimental lung silicosis. Am. J. Respir. Crit. Care Med. 160 (1999) 1274-1282
43. Scabilloni J.F., Wang L., Antonini J.M., Roberts J.R., Castranova V., and Mercer R.R. Matrix metalloproteinase induction in fibrosis and fibrotic nodule formation due to silica inhalation. Am. J. Physiol. Lung Cell. Mol. Physiol. 288 (2005) 709-717
44. Van Wart H.E., and Birkedal-Hansen H. The cysteine switch: A principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. USA 87 (1990) 5578-5582
45. Moutsiakis D., Mancuso P., Krutzsch H., Stetler-Stevenson W., and Zucker S. Characterization of metalloproteinases and tissue inhibitors of metalloproteinases in human plasma. Connect. Tissue Res. 28 (1992) 213-230